DSpace Repository

Additional evidence to support the phasing-out of treatment category II regimen for pulmonary tuberculosis in Peru

Show simple item record

dc.contributor.author Ponce, M.
dc.contributor.author Ugarte Gil, Cesar Augusto
dc.contributor.author Zamudio Fuertes, Carlos Eduardo
dc.contributor.author Krapp, F.
dc.contributor.author Gotuzzo Herencia, José Eduardo
dc.contributor.author Seas Ramos, Carlos Rafael
dc.date.accessioned 2022-01-18T19:26:48Z
dc.date.available 2022-01-18T19:26:48Z
dc.date.issued 2012
dc.identifier.uri https://hdl.handle.net/20.500.12866/10892
dc.description.abstract The effectiveness of the World Health Organization's (WHO) treatment category II regimen for tuberculosis in 124 patients was compared to that of 1147 patients receiving treatment category I in Lima, Peru following WHO's guidelines. Drug susceptibility test was available for 85% of patients. Prevalence of multi drug resistance and streptomycin resistance were 5.1% and 20.7%, respectively. Overall cure rate for regimen II was lower than that of regimen I: 67.8% (95% CI: 58.9-75.6.) vs 77.8% (95% CI: 75.3-80.2), p = 0.014. Multi-drug resistance exerted a profound effect on cure rates in both regimens. Our results support the phasing-out of treatment category II regimen in Peru. en_US
dc.language.iso eng
dc.publisher Oxford University Press
dc.relation.ispartofseries Transactions of the Royal Society of Tropical Medicine and Hygiene
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Humans en_US
dc.subject Peru en_US
dc.subject Major Clinical Study en_US
dc.subject Rifampicin en_US
dc.subject Prevalence en_US
dc.subject Tuberculosis en_US
dc.subject Lung Tuberculosis en_US
dc.subject Tuberculosis Pulmonary en_US
dc.subject Treatment Outcome en_US
dc.subject Antitubercular Agents en_US
dc.subject Streptomycin en_US
dc.subject Tuberculosis Multidrug-Resistant en_US
dc.subject Drug Administration Schedule en_US
dc.subject World Health Organization en_US
dc.subject Multidrug Resistance en_US
dc.subject Drug Therapy en_US
dc.subject Practice Guidelines As Topic en_US
dc.subject Treatment Failure en_US
dc.subject Evidence-Based Medicine en_US
dc.subject Convalescence en_US
dc.subject Treatment Outcome en_US
dc.subject Failure en_US
dc.title Additional evidence to support the phasing-out of treatment category II regimen for pulmonary tuberculosis in Peru en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.1016/j.trstmh.2012.05.008
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.03.06
dc.relation.issn 1878-3503


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/restrictedAccess Except where otherwise noted, this item's license is described as info:eu-repo/semantics/restrictedAccess

Search DSpace


Browse

My Account

Statistics